C R Bard Inc  

(Public, NYSE:BCR)   Watch this stock  
Find more results for C.R. Bard, Inc
171.30
-1.47 (-0.85%)
Jul 2 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 170.55 - 173.48
52 week 141.49 - 180.94
Open 173.48
Vol / Avg. 339,746.00/367,699.00
Mkt cap 12.72B
P/E 47.09
Div/yield 0.24/0.56
EPS 3.64
Shares 74.25M
Beta 0.70
Inst. own 90%
Jul 23, 2015
Q2 2015 C R Bard Inc Earnings Call - 5:00PM EDT - Add to calendar
Jul 23, 2015
Q2 2015 C R Bard Inc Earnings Release - 4:00PM EDT - Add to calendar
Jun 2, 2015
C R Bard Inc at Jefferies Global Healthcare Conference
May 12, 2015
C R Bard Inc at Bank of America Merrill Lynch Health Care Conference
Apr 23, 2015
Q1 2015 C R Bard Inc Earnings Call - Webcast
Apr 23, 2015
Q1 2015 C R Bard Inc Earnings Release
Apr 15, 2015
C R Bard Inc Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 17.06% 8.86%
Operating margin 23.90% 14.54%
EBITD margin - 28.88%
Return on average assets 11.05% 5.81%
Return on average equity 31.08% 14.88%
Employees 13,900 -
CDP Score - -

Address

730 Central Ave
NEW PROVIDENCE, NJ 07974-1139
United States - Map
+1-908-2778000 (Phone)
+1-908-2778412 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

C. R. Bard, Inc. (Bard) and its subsidiaries are engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. . The Company reports its sales in four major product group categories: vascular, urology, oncology and surgical specialty. The Company also has a product group of other products. The Company's vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and heart arrhythmias. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and other soft tissue repairs, in addition to hemostats and surgical sealants.

Officers and directors

Timothy M. Ring Chairman of the Board, Chief Executive Officer
Age: 57
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John H. Weiland President, Chief Operating Officer, Director
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jim C. Beasley Group President
Age: 51
Bio & Compensation  - Reuters
Timothy P. Collins Group President
Age: 54
Bio & Compensation  - Reuters
Christopher S. Holland Chief Financial Officer, Senior Vice President
Age: 48
Bio & Compensation  - Reuters
Samrat S. Khichi Senior Vice President, General Counsel, Secretary
Age: 47
Bio & Compensation  - Reuters
John A. DeFord Ph.D. Senior Vice President - Science, Technology and Clinical Affairs
Age: 53
Bio & Compensation  - Reuters
Frank Lupisella Jr. Vice President, Controller
Age: 54
Bio & Compensation  - Reuters
Patricia G. Christian Vice President - Quality, Regulatory and Medical Affairs
Age: 54
Bio & Compensation  - Reuters
John P. Groetelaars Group Vice President
Age: 48
Bio & Compensation  - Reuters